Form 4: Bicara Therapeutics Director Kate Haviland Granted Stock Options Valued at $11.48 Per Share

Bicara Therapeutics Inc. Director Kate Haviland was granted 23,746 stock options with an exercise price of $11.48 per share, vesting upon the earlier of June 9, 2026, or the next Annual Meeting of Stockholders.

Summary

• Kate Haviland, a Director of Bicara Therapeutics Inc. (BCAX), was granted 23,746 stock options.
• The options have an exercise price of $11.48 per share.
• The transaction date for this grant was June 9, 2025.
• These options were awarded under the Issuer's 2024 Stock Option and Incentive Plan.
• The shares underlying these options will vest upon the earlier of June 9, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Ms. Haviland's continued service.
• The options are set to expire on June 9, 2035.
• Following this transaction, Ms. Haviland beneficially owns 23,746 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, so not highly impactful on its own.

Positives

• The grant of stock options to a director, Kate Haviland, aligns her interests with those of the shareholders, incentivizing long-term performance and value creation for Bicara Therapeutics.
• The options were granted under the company's 2024 Stock Option and Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

The stock options granted to Director Kate Haviland are subject to future vesting, which will occur upon the earlier of June 9, 2026, or the date of the next Annual Meeting of Stockholders, provided her continued service to the company.

Management Comments

• The option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan.
• The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

Industry Context

The granting of stock options to directors is a common practice across industries, including biotechnology, to attract and retain talent, and to align the interests of board members with those of shareholders. This particular grant is consistent with standard corporate governance practices for director compensation.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism in publicly traded companies, particularly within the biotechnology sector, to incentivize long-term commitment and performance.
• The vesting schedule, tied to either a specific date or the next annual meeting, is also a common structure for director equity awards, similar to practices observed at companies like Moderna (MRNA) or BioNTech (BNTX) for their board members.

Corporate Governance

Related Party Transactions

• The grant of stock options to Kate Haviland, a Director of Bicara Therapeutics Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution upon exercise but is intended to align the director's incentives with long-term shareholder value creation.
• Employees: While not directly impacting employees, the use of an incentive plan for directors may reflect the broader compensation philosophy of the company.

Next Steps

• The granted stock options will vest upon the earlier of June 9, 2026, or the date of the next Annual Meeting of Stockholders, subject to Kate Haviland's continued service.

Key Dates

Keywords

Bicara Therapeutics, BCAX, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, SEC Filing, Biotechnology, Pharmaceuticals